The present invention relates to: a cosmetic composition for improving the condition of the skin, containing, as active ingredients, a cell culture medium, an epidermal growth factor and a bovine serum albumin; a method for improving the condition of the skin by using the same; and a method for preventing or treating skin diseases. According to the present invention, the cosmetic composition can exhibit excellent wrinkle-reducing and wound-healing effects even when only a small amount of EGF is used, and thus can be useful in improving the condition of the skin or in preventing or treating skin diseases.

The invention relates to a nasally administrable composition comprising at least one active substance in magnesium-containing vesicular carrier, said carrier comprising glycol, phospholipids, water and at least one magnesium source. Methods for nasal administration of the composition, for example, for pain relief, are also provided.

In the invention, the minimum inhibitory concentrations of human-originated EGF domain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity. It has been shown that the human-originated EGF domain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by silver staining that the human-originated EGF domain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia. The amino acid sequences of the human-originated EGF domain proteins are the one described in SEQ ID NO: 1 in the sequence listing, or those having homology of over 50% to the amino acid sequence described in SEQ ID NO: 1.

Compositions and methods for topical treatment of hair loss in otherwise normal skin that is affected by alopecia are presented. Such compositions include defensins in concentrations that are below those that exhibit antimicrobial activity, and can be in the form of a topically applied gel, lotion, wash, shampoo, cream, or mask. Various formulations for such compositions, which can include various pharmaceutically acceptable stabilizers, emollients, and fragrances, are provided. Such compositions and methods can be used in conjunction with traditional methods for treatment of hair loss.

Compositions and methods for topical treatment of hair loss in otherwise normal skin that is affected by alopecia are presented. Such compositions include defensins in concentrations that are below those that exhibit antimicrobial activity, and can be in the form of a topically applied gel, lotion, wash, shampoo, cream, or mask. Various formulations for such compositions, which can include various pharmaceutically acceptable stabilizers, emollients, and fragrances, are provided. Such compositions and methods can be used in conjunction with traditional methods for treatment of hair loss.

Methods of using an ET.sub.B receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ET.sub.B receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.

Methods of using an ET.sub.B receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ET.sub.B receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.

The present invention discloses novel ophthalmic preparations for the treatment of corneal pathologies comprising umbilical cord blood plasma.

Provided is a novel material used to introduce an exogenous substance into cells. Also provided is a method for introducing an exogenous substance into target cells using this material. The present invention provides an exosome that is used to introduce an exogenous substance into target cells, wherein the exosome contains one type or two or more types of an exogenous substance and a substance that induces macropinocytosis in the target cells. The present invention also provides a composition containing the exosome and a method for introducing an exogenous substance into cells using this exosome.

Methods and compositions for treating Middle East respiratory syndrome coronavirus (MERS-CoV) infection using polypeptides having sialidase activity are provided herein.